Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS

[1]  J. Cerhan,et al.  Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications. , 2010, Blood.

[2]  B. Barlogie,et al.  Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management , 2010, Leukemia.

[3]  M. Drayson,et al.  Assessment of monoclonal gammopathies by nephelometric measurement of individual immunoglobulin kappa/lambda ratios. , 2009, Clinical chemistry.

[4]  R. Howard,et al.  A monoclonal gammopathy precedes multiple myeloma in most patients. , 2009, Blood.

[5]  R. Hayes,et al.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. , 2009, Blood.

[6]  A. Órfão,et al.  New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. , 2007, Blood.

[7]  Terry M Therneau,et al.  Prevalence of monoclonal gammopathy of undetermined significance. , 2006, The New England journal of medicine.

[8]  T. Therneau,et al.  Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. , 2005, Blood.

[9]  Raimund J Ober,et al.  Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans. , 2003, International immunology.

[10]  C. Klersy,et al.  Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Terry M Therneau,et al.  A long-term study of prognosis in monoclonal gammopathy of undetermined significance. , 2002, The New England journal of medicine.

[12]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.

[13]  R. Kyle,et al.  Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. , 1978, The American journal of medicine.

[14]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[15]  R A Kyle,et al.  Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma , 2014, Leukemia.

[16]  D.,et al.  Regression Models and Life-Tables , 2022 .